Two for the price of one: Attacking the energetic-metabolic hub of mycobacteria to produce new chemotherapeutic agents. (May 2020)

• Record Type: Journal Article
• Authors: Hards, Kiel; Adolph, Cara; Harold, Liam K.; McNeil, Matthew B.; Cheung, Chen-Yi; Jinich, Adrian; Rhee, Kyu Y.; Cook, Gregory M.
• Is Part Of: Progress in biophysics and molecular biology. Volume 152(2020)
• Page Start: 35
• Page End: 44
• Publication Date: 2020-05
• Subjects: Tuberculosis -- Succinate dehydrogenase -- Fumarate reductase -- malate:quinone oxidoreductase -- Mycobacteria; Biophysics -- Periodicals; Biochemistry -- Periodicals; Biophysics -- Periodicals; Molecular Biology -- Periodicals; Biophysique -- Périodiques; Biochimie -- Périodiques; 571.4
• DOI: 10.1016/j.pbiomolbio.2019.11.003
• Languages: English
• ISSNs: 0079-6107

Abstract

Abstract: Cellular bioenergetics is an area showing promise for the development of new antimicrobials, antimalarials and cancer therapy. Enzymes involved in central carbon metabolism and energy generation are essential mediators of bacterial physiology, persistence and pathogenicity, lending themselves natural interest for drug discovery. In particular, succinate and malate are two major focal points in both the central carbon metabolism and the respiratory chain of Mycobacterium tuberculosis . Both serve as direct links between the citric acid cycle and the respiratory chain due to the quinone-linked reactions of succinate dehydrogenase, fumarate reductase and malate:quinone oxidoreductase. Inhibitors against these enzymes therefore hold the promise of disrupting two distinct, but essential, cellular processes at the same time. In this review, we discuss the roles and unique adaptations of these enzymes and critically evaluate the role that future inhibitors of these complexes could play in the bioenergetics target space.